BioSpace News Archive

Oxurion NV announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:

Rapid Dose Therapeutics Corp., a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, is announcing changes to its board of directors.

Aadi Bioscience, Inc. (NASDAQ: AADI) today announced the presentation of three posters at the 2023 American Association for Cancer Research Annual Meeting (AACR), taking place April 14-19, 2023, in Orlando, FL.

Agena Bioscience and nRichDX have advanced their existing technical collaboration to a commercial partnership that co-promotes their products to researchers developing liquid biopsy applications on the Agena MassARRAY platform.

HOOKIPA Pharma Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-statutory options to a new employee to purchase an aggregate of 50,000 shares of the Company’s Common Stock under HOOKIPA’s 2023 Inducement Plan.

PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, announced it has received a letter from the Listing Qualifications staff of The Nasdaq Stock Market notifying the Company that it is no longer in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Global Market.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced multiple scientific presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held April 23 - 27 in New Orleans, Louisiana.

InflaRx N.V. announced that it has completed its underwritten public offering of 9,411,765 ordinary shares at a public offering price of $4.25 per ordinary share.

Lifecore Biomedical, Inc. announced that it received a notice on April 13, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market stating that the Company is not in compliance with Nasdaq Listing Rule 5250 because the Company failed to timely file its Quarterly Report on Form 10-Q for the period ended February 26, 2023 with the Securities and Exchange Commission.

Predicine, a global molecular insights company, announced that it will present data from 12 studies and introduce PredicineALERT™, a next-generation Minimal Residual Disease liquid biopsy assay at the 2023 AACR Conference on April 14-19, 2023.